Private Wealth Partners LLC Boosts Holdings in Zoetis Inc. (NYSE:ZTS)

Private Wealth Partners LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,256 shares of the company’s stock after acquiring an additional 880 shares during the quarter. Zoetis makes up 2.1% of Private Wealth Partners LLC’s investment portfolio, making the stock its 16th largest position. Private Wealth Partners LLC’s holdings in Zoetis were worth $25,117,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Capital Investment Advisors LLC grew its holdings in shares of Zoetis by 38.1% during the third quarter. Capital Investment Advisors LLC now owns 2,263 shares of the company’s stock worth $394,000 after buying an additional 624 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Zoetis during the third quarter worth about $214,000. Coastline Trust Co grew its holdings in shares of Zoetis by 2.9% during the third quarter. Coastline Trust Co now owns 4,547 shares of the company’s stock worth $791,000 after buying an additional 127 shares in the last quarter. Czech National Bank grew its holdings in shares of Zoetis by 47.1% during the third quarter. Czech National Bank now owns 80,453 shares of the company’s stock worth $13,997,000 after buying an additional 25,748 shares in the last quarter. Finally, Aaron Wealth Advisors LLC purchased a new stake in shares of Zoetis during the third quarter worth about $211,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 2,209 shares of company stock worth $371,293 over the last 90 days. Insiders own 0.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ZTS shares. Barclays lowered their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. The Goldman Sachs Group lifted their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler reissued an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Stifel Nicolaus decreased their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $218.00.

Zoetis Trading Up 3.3 %

Shares of ZTS traded up $5.06 during mid-day trading on Friday, hitting $158.42. The company had a trading volume of 5,236,463 shares, compared to its average volume of 4,019,007. The business’s 50-day simple moving average is $171.79 and its 200-day simple moving average is $179.31. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock has a market cap of $72.45 billion, a PE ratio of 31.25, a P/E/G ratio of 2.42 and a beta of 0.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter last year, the firm posted $1.15 EPS. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. Sell-side analysts forecast that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.09%. Zoetis’s payout ratio is 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.